1-(5-Methyl-1-phenyl-4-pyrazolyl)-3-[4-(o-tolyl)-piperazinyl]-1-propanone,a new synthetic antihypertensive agent

Zusammenfassung 1-(5-Methyl-1-phenyl-4-pyrazolyl)-3-[4-(o-tolyl)-piperazinyl]-1-propanone (I; CIBA 1002-Go), senkt an normotonischen und hypertonischen Tieren den Blutdruck. Die Drucksenkung kann auf eine periphere Vasodilatation und eine Hemmung hypothalamischer oder medullärer Vasomotorenzentren bezogen werden. Ausserdem wirkt CIBA 1002-Go adrenolytisch.

---

---

Hydrochloride = CIBA 1002-Go.     

Pathogenesis and therapy of psoriasis

Psoriasis is one of the most common human skin diseases and is considered to have key genetic underpinnings. It is characterized by excessive growth and aberrant differentiation of keratinocytes, but is fully reversible with appropriate therapy. The trigger of the keratinocyte response is thought to be activation of the cellular immune system, with T cells, dendritic cells and various immune-related cytokines and chemokines implicated in pathogenesis. The newest therapies for psoriasis target its immune components and may predict potential treatments for other inflammatory human diseases.